Trials / Completed
CompletedNCT01424397
Intranasal SB-705498 in Allergic Rhinitis (AR) Patients
A Randomized, Double-blind, Placebo Controlled, Incomplete Block, 3 Way Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Intranasal Repeat Doses of SB-705498 When Administered Alone or in Conjunction With Intranasal Fluticasone Propionate on the Symptoms of Rhinitis in the Vienna Allergen Challenge Chamber
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms induced by an allergen chamber challenge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-705498 | 12mg intranasal |
| DRUG | FP | 200ug intranasal |
| DRUG | placebo | placebo intranasal |
Timeline
- Start date
- 2011-04-14
- Primary completion
- 2011-07-07
- Completion
- 2011-07-07
- First posted
- 2011-08-29
- Last updated
- 2019-09-13
- Results posted
- 2019-09-13
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT01424397. Inclusion in this directory is not an endorsement.